Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Neurol ; 21(10): 1285-91, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24909847

ABSTRACT

BACKGROUND AND PURPOSE: Orolingual angioedema (OA) is an uncommon but potentially life-threatening complication of treatment with recombinant tissue plasminogen activator (rt-PA; alteplase) during acute ischaemic stroke. This study aimed to determine the incidence of rt-PA-related OA in an Asian stroke population and the risk of pre-stroke anti-hypertensive drug use for development of this complication. METHODS: A multi-center stroke registry was used to identify the pre-stroke medications of acute ischaemic stroke patients receiving intravenous rt-PA from January 2002 to December 2013. The clinical manifestations of rt-PA-related OA were recorded and the incidence of this complication was determined. The risks of pre-stroke use of different anti-hypertensive agents for the occurrence of rt-PA-related OA were determined from this study and from a meta-analysis. RESULTS: A total of 559 patients received intravenous rt-PA over a 12-year period. Five patients (two males) developed OA after rt-PA administration. The incidence of OA amongst these patients was 0.89% (95% confidence interval 0.29%-2.09%), which was lower than that obtained by meta-analysis (1.9%). Amongst pre-stroke anti-hypertensive medications, angiotensin-converting enzyme (ACE) inhibitors were found in this study to have the highest relative risk for rt-PA-related OA (17.1; 95% confidence interval 3.0-96.9). Meta-analysis also revealed that pre-stroke use of ACE inhibitors was associated with a high relative risk of OA after intravenous rt-PA (12.9; 95% confidence interval 4.5-37.0). CONCLUSIONS: The incidence of rt-PA-related OA in the Asian population is lower than that in the Caucasian population. Pre-stroke use of ACE inhibitors significantly increases the risk of this complication.


Subject(s)
Angioedema/chemically induced , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Brain Ischemia/drug therapy , Fibrinolytic Agents/adverse effects , Mouth Diseases/chemically induced , Registries/statistics & numerical data , Stroke/drug therapy , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/adverse effects , Aged , Aged, 80 and over , Angioedema/epidemiology , Brain Ischemia/epidemiology , Female , Fibrinolytic Agents/administration & dosage , Humans , Incidence , Male , Middle Aged , Mouth Diseases/epidemiology , Risk , Stroke/epidemiology , Taiwan/epidemiology , Thrombolytic Therapy/statistics & numerical data , Tissue Plasminogen Activator/administration & dosage , Tissue Plasminogen Activator/therapeutic use , Tongue Diseases/chemically induced , Tongue Diseases/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...